![[MeMed in PR Newswire] MeMed Secures Additional Funding From the Department of Defense](https://blog.ourcrowd.com/wp-content/uploads/2017/09/PR_newswire.jpg)
MeMed Ltd. announced today that it has been awarded a $4,079,159 grant by the DoD’s Congressionally Directed Medical Research Programs (CDMRP). Read more on PR...
Read More
MeMed today announced positive results from a large, external double-blinded PATHFINDER study that met its primary endpoint, independently confirming that MeMed’s novel blood test, ImmunoXpert™, accurately distinguishes between bacterial and viral infections in children. Read more on PR...
Read More![[MeMed in Molecular Diagnostics Europe] Redefining the Set of Solutions for Antibiotics Misuse Using Host Response-Based Diagnostics](https://blog.ourcrowd.com/wp-content/uploads/2018/04/molecular-diagnostics.png)
Dr. Kfir Oved outlines some of the greatest obstacles to controlling antibiotic misuse, advice for introducing new products in the clinical setting, describes some of the most exciting new developments emerging for AMR, and summarizes what he is looking forward to at the Advanced Diagnostics for Infectious Disease track at Molecular Diagnostics Europe Summit. Read more on Molecular Diagnostics...
Read More
MeMed Ltd. announced today that it has been awarded a contract by the Defense Threat Reduction Agency (DTRA), a branch of the US Department of Defense (DoD). Read more on PR...
Read More![[MeMed in Longitude Prize] Bacterial or viral: To treat or not to treat with antibiotics](https://blog.ourcrowd.com/wp-content/uploads/2018/04/longitude-prize_one-line-logo_2_1300x200.png){kind=logo}
Over 10 years ago, we decided to take on the challenge of developing a new tool that can help clinicians decide if an infection is bacterial or viral, and founded a biotech company, MeMed. Read more on Longitude Prize...
Read More
